Medicaid gender-care ban creates 17-state legal collision

For regulatory and constitutional law practitioners, this is not just a healthcare story—it is a live test of federal spending power and administrative agency authority. CMS's new rule forces 17 states to choose between their own coverage mandates and federal Medicaid dollars, a conflict that almost certainly ends in federal court. The AMA's letter and state-level statutes create the predicate for APA and constitutional challenges that could redraw the boundaries of federal health policy.

The Centers for Medicare and Medicaid Services is implementing a new rule that prohibits the use of federal Medicaid dollars to fund what it calls 'sex-rejecting procedures' for individuals under age 18. The prohibition extends to the Children's Health Insurance Program (CHIP) and covers gender transition surgery, puberty blockers, and cross-sex hormones for minors. CMS Administrator Dr. Mehmet Oz introduced the policy in a video on Tuesday, warning that the procedures can cause infertility, impaired sexual function, diminished bone density, and other irreversible effects. The announcement writes into federal policy a position President Donald Trump has promoted since at least June 2023, when he campaigned on revoking the prior administration's gender-affirming care policies. In a March 2025 speech to Congress, he asked lawmakers to permanently ban and criminalize sex changes on children. The rule does not criminalize care, but it uses federal funding authority to restrict access.

“

CMS's new rule forces 17 states to choose between their own coverage mandates and federal Medicaid dollars, a conflict that almost certainly ends in federal court.

Medicaid is a shared federal-state program. The federal government sets conditions on matching funds, while states administer coverage within those rules. By withholding federal financial participation for specific services provided to minors, the CMS rule forces states into a difficult choice: use state-only dollars to continue coverage, alter their Medicaid and CHIP programs, or accept the federal restriction. The article reports that 17 states currently cover some degree of gender transition care for minors. That creates a direct collision between state health policy and federal reimbursement rules. States that wish to continue coverage will need to examine state plan amendments, waivers, and budget allocations. Those that comply will shift treatment protocols, provider networks, and patient eligibility.

The rule also opens a significant legal and administrative front. The American Medical Association wrote to the administration earlier this year asking that the rule be rescinded. The AMA argued that the necessity of medical procedures should not be determined by a government entity, but by treating physicians, to ensure medical decisions are made appropriately. This sets up a classic challenge under the Administrative Procedure Act: opponents may argue the rule is arbitrary and capricious, unsupported by a balanced reading of medical evidence, and inconsistent with statutory protections for Medicaid beneficiaries. Federalism concerns will also arise because the rule conditions billions of dollars in matching funds on state adoption of a contested policy. Spending Clause and equal protection claims could follow, particularly if challengers argue the rule discriminates based on sex or transgender status.

The factual dispute over safety and necessity is central. Some board-certified physicians, including plastic surgeon Dr. Ira Savetsky, argue that irreversible and life-altering surgeries on minors require overwhelming evidence and that the evidence has not met that standard. Dr. Oz and the CMS point to specific risks such as infertility and reduced bone density. The AMA and other opponents counter that evidence-based care, individualized assessment, and existing standards of care already manage those risks, and that denying coverage will cause mental health harms. This is not simply a partisan fight; it reflects a real disagreement within medicine about the strength of evidence, the role of precaution, and the proper scope of federal payment policy.